Top Tweets for #GEPNETs
Tuning in from across the pond #ESMO25...
#ALPHAMEDIX02: 212Pb-DOTAMTATE in pts w/ #GEPNETs previously treated w/ #PRRT.
✅iORR 35%, cORR 19%, 18 month PFS 82%
🚨42% G3+ TRAEs, 15% G3+ dysphagia
How will other alpha RLTs stack up in post-PRRT space? @NANETS1 @NCFCancer @myESMO
Featured expert Jonathan R. Strosberg, MD, of @MoffittNews shares his thoughts on imaging-based predictive models for PRRT in #GastroenteropancreaticNeuroendocrineTumors, reviewing data from the recent 2025 @SNM_MI Annual Meeting.
#SNMMI25 #GEPNETS
https://t.co/nmP1cXqvjd
Jonathan R. Strosberg, MD, of @MoffittNews discusses sequencing PRRT in patients with #GastroenteropancreaticNeuroendocrineTumors and includes information presented at the 2025 @SNM_MI Annual Meeting.
#SNMMI25 #GEPNETS #Oncology #MedEd #md #MedTwitter
https://t.co/9we1eBzBLk
We issued a new guideline on Symptom Management for Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors.
Read full article: https://t.co/i9aEMMXW87
#GEPNets
Don’t miss the chance to review the #CAPguideline draft statements on the Evaluation of #GEPNETs: https://t.co/nItq9BscDQ
Oral presentation at #ENETS2025 by @Ja_Capdevila
Randomised phase III #COMPETE trial in G1-2 #GEPNETs
177LuEdoteotride vs Everolimus
🥳PFS data favours PRRT (HR 0.67)
👉OS promising
👍🏻Safety not an issue
👏🏻SSA ONLY for functioning (finally 😉)
@ENETS_ORG @GrupoGetne
"Real-World Study of Lanreotide Autogel in Routine Practice in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Hong Kong and Taiwan"
Read #openaccess here, alongside an associated #PLS: https://t.co/4sTJ9DBQho
#GEPNETs #Neuroendocrine
Day 3 of #DDHO2024 kicks off with a triple-header of debates: #gastroesophagealcancer #GEPNETs #pancreaticcancer
@WinshipAtEmory
Beautiful session in #ESMOGI24 on #GEPNETs chaired by @RachelRiechelm2 @Juanmaoconnor
Lots on 🔪surgery, ☢️PRRT and 💊systemic therapies, BUT MOST IMPORTANTLY, we learned how to put it all into #context and #individualise
@myESMO #ESMOAmbassadors @GrupoGetne
🚨 Breaking news: The @US_FDA has approved the use of lutetium Lu 177 dotatate for the treatment of SSTR-positive GEP-NETs in pediatric patients based on positive trial results. Learn more: https://t.co/iEbM3vIXi9
#Lu177 #GEPNETS #Gastrointestinal #FDA
🎉 Wow, congrats to my amazing mentee for his work on evaluating real-world results of PRRT in GEP-NETs! The significant findings for a unique patient subset are intriguing . So proud to be your mentor, @StijnHentzen ! 🙌 @CureNETs #NETCancer #Carcinoid #GEPNETs #NETsResearch
Recently published work evaluating real world results of PRRT in GEP-NETs.
Promising results with significant findings regarding a unique subsection of patients.
Thankful for the mentorship of @anup_kasi
Part 2 of 2
How can radiopharmaceuticals be best used in the management of adult solid tumours?
Join @drjasonstarr Prof. Jorge Garcia and @ErikMittraMD as they share their insights.
Watch now: https://t.co/1muW0TcjaM
#Oncology #Radiopharmaceuticals #ProstateCancer #GEPNETs
@PamelaKunzMD novel agents targeting #SSTR, #MGMT deficiency & temodar response, trials to watch in #GEPNETs & #NEC and #PRRT in #GEPNETS @TumorBoardTues and new concept of #PRRT rechallenge #SBNET
@CSCancerCenter 4th Annual GI Tumor conf https://t.co/7s8rEqg0r4 @OncoAlert
Today we announced that the first patient has been treated in our 2nd phase III clinical trial, COMPOSE, evaluating our lead #radiopharmaceutical candidate ITM-11 (n.c.a. lutetium-177-edotreotide) for the treatment of #GEPNETs. Read the press release at: https://t.co/DimwCY63wE
#SaveTheDate: ITM will be attending the virtual #NANETS symposium, Nov 3-6. Join us as we unveil our second phase III trial, #COMPOSE, evaluating Targeted Radionuclide Therapy compared to best standard of care in well-differentiated aggressive high grade 2 and 3 #GEPNETS.
Visit our new GEP-NETs website at https://t.co/gqtEckovBO to learn more about our two phase III #ClinicalTrials, COMPETE & COMPOSE, evaluating Targeted #Radionuclide Therapy with n.c.a. Lutetium-177-Edotreotide in patients living with #GEPNETs.
Did you know that #GEPNETs are often asymptomatic & diagnosed late-stage with #metastases & limited possibility for surgical removal? We are addressing this high unmet medical need with our pipeline & clinical trials. More info on our GEP-NETs website: https://t.co/gqtEckG6tm
Our @AACR e-poster featuring COMPETE, our pivotal Ph III #ClinicalTrial evaluating PRRT in #GEPNETs, will be available from April 10 8:30 am ET / 2:30 pm CET - June 21. Our Deputy CMO will be on hand for questions & discussions. See the full PR here: https://t.co/8axJxFdeQ0
GETNE-TRASGU 9-clinical variables nomogram allows stratification of patients with advanced #GEPNETs receiving #SSA according to their estimated PFS and it could be a valuable tool for making treatment decisions in daily clinical practice. #Oncoalert https://t.co/ePOvAysbHN
Last Seen Hashtags on Sotwe
thatsyourmom
Seen from Italy
BurcuÖzberk
Seen from Turkey
momson #xlii
Seen from Malaysia
TEENAGE filter:videos
Seen from Turkey
exny()()*
Seen from Singapore
ヴァラク・クララ
Seen from United States
antakyaesc
Seen from Turkey
sexsedarah
Seen from Canada
socal
Seen from United States
LakeShow
Seen from Brazil
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
240.2M followers
Barack Obama
@barackobama
119.3M followers
Donald J. Trump
@realdonaldtrump
111.6M followers
Cristiano Ronaldo
@cristiano
108.9M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
97.3M followers
NASA
@nasa
92.1M followers
Justin Bieber
@justinbieber
90.6M followers
KATY PERRY
@katyperry
86.8M followers
Taylor Swift
@taylorswift13
80.6M followers
Lady Gaga
@ladygaga
72.2M followers
Kim Kardashian
@kimkardashian
69.4M followers
YouTube
@youtube
68.6M followers
Virat Kohli
@imvkohli
68.5M followers
Bill Gates
@billgates
63.4M followers
The Ellen Show
@theellenshow
62.5M followers
CNN
@cnn
61.9M followers
Neymar Jr
@neymarjr
61.1M followers
X
@x
60.9M followers
Selena Gomez
@selenagomez
59.9M followers